



NAMS NEWS

Call for 2004 Abstracts

NAMS invites researchers to submit their basic science, clinical, epidemiologic, and education abstracts for consideration by the 2004 Abstract Review Committee. "We've continued the popular online submission process through the NAMS Web site," said Elizabeth K. Slogar, NAMS Operations Manager and coordinator of the abstract program. "The deadline is **April 15.**"

NAMS Thanks 2003 Partners in Menopause Education

The editors regret that a previous issue provided only a partial list of the 15 companies that demonstrated their support of NAMS' educational efforts by joining the 2003 Partners in Menopause Education program. The complete list is as follows: Aventis Pharmaceuticals; Berlex Laboratories, Inc.; Duramed Pharmaceuticals, Inc.; Eli Lilly and Company; Emerita

Division—Transitions for Health Inc.; GlaxoSmithKline Consumer Healthcare; Merck & Co., Inc; Monarch Pharmaceuticals, Inc.; Noven Pharmaceuticals, Inc.; Pfizer Inc.; Pharmaton Natural Health Products; Procter & Gamble Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Warner Chilcott, Inc.; and Wyeth Pharmaceuticals. NAMS appreciates this support.

NAMS Exam Update

All licensed healthcare providers are invited to sit for the NAMS Menopause Practitioner competency examination. Join hundreds of your colleagues who have earned this prestigious credential. Demonstrate to your community that you have special competency in the field.

The next examination date is **May 15**; applications must be postmarked by **March 5** (April 9 with payment of a late fee). Locations include: Los Angeles, Oakland, Chicago, New Orleans, Detroit, Clark (NJ), New York, Cleveland, Cincinnati, Philadelphia, Houston, and Ottawa (Canada). The final 2004 exam date is **October 6** in Washington, DC, just prior to the NAMS Annual Meeting. Download a copy of the *Candidate Handbook* (www.menopause.org/compexam.html) and submit your application soon.

Award Winners Recognized

At its 13th Annual Meeting, NAMS recognized outstanding research efforts with the following awards and grants. The Society congratulates these deserving recipients and thanks industry for its unrestricted grants that helped make many of the awards possible.

2003 Top Posters—Basic Science: **Benjamin C. Wong, MD**, Norfolk, VA, for "Effects of Estradiol and Raloxifene in Thrombospondin-1 mRNA Levels in MCF-7 Breast Cancer Cells." Clinical: **Carlos Ramos, MD**, Houston, TX, for

Plan Ahead

15th NAMS Annual Meeting

October 6–9, 2004
Washington, DC

16th NAMS Annual Meeting

September 28–October 1, 2005
San Diego, CA

"Cetirizine (Zyrtec) in the Management of Hot Flashes in Postmenopausal Women: A Randomized, Controlled Trial."

2003 NAMS New Investigator Awards—Recognizing the outstanding abstract submissions of four investigators who have achieved their degree within the past 7 years: **Julie A. Elder, DO**, Cleveland, OH; **Janet R. Guthrie, PhD**, Parkville, Victoria, Australia; **Gail A. Laughlin, BS**, La Jolla, CA; **Charles E. Wood, PhD**, Winston-Salem, NC.

2004 NAMS/Solvay Pharmaceuticals, Inc. Clinical Research Fellowship Grant—Awarded to **Silvina M. Bocca, MD, PhD, HCLD**, Norfolk, VA, for her research project entitled "Effects of Doxycycline on Endometrial Fluid and Tissue as well as Peripheral Blood Concentrations on Matrix Metalloproteinases, Tumor Necrosis Factor, and Vascular Endothelial Growth Factor in Postmenopausal Women Using Oral Continued Estrogens and Medroxyprogesterone Acetate Daily." Research begins January 2004.

2003 NAMS/Berlex Laboratories Award for Innovations in Perimenopausal Contraception—Acknowledging an individual whose research has made an innovative contribution to the understanding of the role of contraceptive use in women over age 40: **David F. Archer, MD**, Norfolk, VA.

2003 NAMS/GlaxoSmithKline Consumer Healthcare Education Excellence Award—

NAMS Central Office:

The North American
Menopause Society
5900 Landerbrook Drive, Suite 195
Mayfield Heights, OH 44124

Mailing Address:
Post Office Box 94527
Cleveland, OH 44101-4527

Phone: 440/442-7550
Fax: 440/442-2660

E-mail Address: info@menopause.org
Web Site: <http://www.menopause.org>

Recognizing and acknowledging a consumer health educator among the NAMS membership who has made a significant contribution toward improving the quality of life of menopausal women: **Elaine E. Jolly, MD**, Ottawa, ON, Canada.

2003 NAMS/Eli Lilly and Company Award for Innovations in Osteoporosis—Recognizing an individual for his/her body of work relating to the diagnosis, prevention, and/or treatment of postmenopausal osteoporosis: **Ethel S. Siris, MD**, New York, NY.

2003 NAMS/Eli Lilly and Company SERM Research Award—Recognizing an individual for his/her body of work relating to SERMs for any indication, including osteoporosis: **V. Craig Jordan, OBE, PhD, DSc**, Evanston, IL.

2003 NAMS/Duramed Pharmaceuticals Perimenopause Research Award—Recognizing an individual whose research has advanced the understanding of perimenopause: **Nancy Fugate Woods, PhD, RN**, Seattle, WA.

2003 NAMS/Endeavor Pharmaceuticals Vasomotor Symptoms Research Award—Recognizing an individual whose research has made significant contributions toward increasing the understanding of menopause-related vasomotor symptoms: **Howard L. Judd, MD**, Los Angeles, CA.

2003 NAMS/Warner Chilcott Vaginal Health Research Award—Recognizing an individual whose research has made significant contributions toward increasing the understanding of vaginal health in peri- and postmenopausal women: **Gloria A. Bachmann, MD**, New Brunswick, NJ.

2003 NAMS/Procter & Gamble Pharmaceuticals Androgen Research Award—Recognizing an individual whose research has advanced the under-

standing of the role of androgen (endogenous or exogenous) in postmenopausal women: **Susan R. Davis, MBBS, PhD**, Clayton, Victoria, Australia.

2003 NAMS/Procter & Gamble Pharmaceuticals Leadership Award in Androgen Research—Recognizing an individual whose body of research over his/her lifetime has advanced the understanding of the role of androgen (endogenous or exogenous) in postmenopausal women: **Morrie M. Gelfand, CM, MD**, Montreal, QC, Canada.

2003 NAMS/Pfizer Cardiovascular Research Award—Recognizing an individual whose body of research has advanced the understanding of cardiovascular health in postmenopausal women: **Thomas B. Clarkson, DVM**, Winston-Salem, NC.

2003 NAMS/Watson Pharma Postmenopausal Overactive Bladder Research Award—Designed to acknowledge quality research regarding the condition of overactive bladder in postmenopausal women: **Stuart Stanton, MD**, London, England.

2003 NAMS Media Award—Designed to recognize a media professional whose body of work, through any consumer media outlet (ie, print, television, radio, Internet), has served to expand the knowledge and understanding of menopause: **Ms. Sally Squires, The Washington Post**, Washington, DC.

2003 NAMS/Wyeth Pharmaceuticals Nurse Practitioner Reporter Program—**Mindy Carroll, RNC, MSN, WHNP**, Nashville, TN; **Carrie Dennison, ANP**, Tualatin, OR; **Karen Dillinger, NP**, Setauket, NY; **Cindy Foster, CNP**, Florence, KY; **Cathy R. Kessenich, DSN, ARNP**, Tampa, FL; **Cathy Lesk, RN, CME**, Ottawa, Ontario, Canada; **Lotta Lindh-Astrand, NP**, Linkoping, Swe-

den; **Gail Marshall, ARNP, MSN**, South Miami, FL; **Helene Mongauzy, BScN, CME**, Ottawa, Ontario, Canada; **Gail Roberts, RN, BN**, Winnipeg, Manitoba, Canada.

ADVERTISERS' INDEX

Aventis Pharmaceuticals

Actonel IBC, OBC

Duramed Pharmaceuticals, Inc. a subsidiary of Barr Laboratories, Inc.

Cenestin32a, 32b

Merck & Co., Inc.

Fosamax.....16a, 16b, 17

King Pharmaceuticals

Prefest.....20-22

Novo Nordisk Pharmaceuticals, Inc.

Activella.....11-12

Vagifem29-30

Watson Pharma, Inc.

Oxytrol8a, 8b

Wyeth Pharmaceuticals

PremproIFC, 1-3